Cyclophosphamide is a neo-adjuvant chemotherapy used with success in association with pembrolizumab in metaplastic triple-negative breast cancer [45], but cyclophosphamide is also known as a ferroptosis inducer because cyclophosphamide-induced GPX4 degradation triggers parthanatos by activating AIFM1 [46] and also acts on Heme Oxygenase-1 [47]. The gene discussed is AIFM1; the disease is triple-negative breast carcinoma.